Westlake Genetech Presents at 2025 Biotech Showcase™

Westlake Genetech will share its achievements in AI-powered gene therapy at the 2025 Biotech Showcase™.

Meeting Core Information

• Meeting Name: 2025 Biotech Showcase™
• Date: Wednesday, January 15, 2025
• Time: 10:45 AM (Local Time)
• Venue: Franciscan B (Ballroom Level), Hilton San Francisco - Union Square

Following its successful participation and presentation at the 2024 Biotech Showcase™, Westlake Genetech will join the biotech gathering for its outstanding contributions to the AI-driven biotechnology. At this year's event, the company will focus on sharing achievements of AI-powered gene therapy.

Over the past year, its leading AAV gene therapy delivery platform has achieved significant breakthroughs, successfully generating a variety of tissue-specific AAVs. These target muscles, the CNS, eyes, and other tissues, unlocking broader clinical applications for gene therapy. Additionally, the company has launched multiple high-fidelity, high-efficiency, and miniaturized gene editing enzymes with independent intellectual property rights. Combined with an AI-assisted sgRNA design system, these tools provide differentiated and competitive solutions to address the safety and delivery bottlenecks of in vivo gene editing.

Westlake Genetech aims to fully showcase its strengths and growth potential in biotechnology, foster in-depth exchanges and close collaborations with industry partners and investors, explore future cooperation opportunities, and collectively drive innovative breakthroughs and development in the sector.

About Biotech Showcase™

Biotech Showcase™ is an investor conference hosted by Demy-Colton and EBD Group. As a leading business development and investment platform for international investors and biomedical innovators, the conference facilitates meetings with investors and biopharmaceutical executives worldwide, solidifying its position as one of the largest annual medical investor events in the industry.

About Westlake Genetech

Westlake Genetech is an innovative biotech company focused on leveraging AI to accelerate the research and development of next-generation gene therapies. Through the proprietary gene therapy technology platforms, the company has achieved significant technological breakthroughs in capsid engineering and payload redesigning, including novel AAV variants with tropism for T cells, CNS and muscle tissues, as well as optimized gene-editing tools. These innovations will help drive the development of safer, more accessible and more efficient gene therapies to address more unmet needs.

Contacts: bd@westlakegenetech.com